Navigation Links
Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
Date:10/29/2009

--- --- --- --- --- Total operating expenses 12,953 18,387 39,701 55,174 246,287 ------ ------ ------ ------ ------- Loss from operations (9,300) (13,474) (29,079) (40,292) (214,655) Other income (expenses): Interest income 1,019 129 4,053 924 13,684 Interest expense (49) (84) (179) (155) (1,802) Change in fair value of warrant liability - - - - (454) Other expense - - - - (1,180) --- --- --- --- ----- Loss before tax benefit (8,330) (13,429) (25,205) (39,523) (204,407) Benefit from income taxes 150 - - - 695 --- --- --- --- --- Net loss (8,180) (13,429) (25,205) (39,523) (203,712) Deemed dividend - - - - (19,424) Preferred stock accretion - - - - (802) --- --- --- --- --- Net loss attributable to common stockholders $(8,180) $(13,429) $(25,205) $(39,523) $(223,938) ======= ======== ======== ======== ========= Net loss attributable to common stockholders per common share - basic and diluted $(0.36) $(0.59) $(1.12) $(1.75) ====== ====== ====== ====== Weighted-average common shares outstanding - basic and diluted 22,517,431 22,621,513 22,465,981 22,617,808 ========== ========== ========== ========== Table 2
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... September 30, 2014 Today the ... round of grants for the Brain Research through ... aims to develop and revolutionize new methods of ... the human brain. This first round of grants ... 2014 was allocated to more than 100 investigators ...
(Date:10/1/2014)... VA (PRWEB) October 01, 2014 ... Diagnostic, Clinical Therapeutics, Healthcare IT, and Laboratory Testing industries, ... regulatory positions at the director level and above from ... struggling to stay on top of rapid breakthroughs in ... result, many diagnostic companies have been forced to fold, ...
(Date:10/1/2014)... , October 1, 2014 ... software invited to engage around the theme, ,Commercial Opportunities ...   Elsevier , a ... and services, will host a gathering of some of ... and trends impacting healthcare today and in the future. ...
(Date:9/30/2014)... analog of one of nature,s most efficient light-harvesting ... led by Alejandro Briseno of the University of ... developing long-sought polymer architecture to boost power-conversion efficiency ... devices. , Briseno, with colleagues and graduate ... University and Dresden University of Technology, Germany, report ...
Breaking Biology Technology:NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3
... England, July 20, 2011 , ... of its randomised, placebo-controlled, double blind Phase II,Study, ... Progressive Multiple Sclerosis (SPMS). Standard clinical,measures and assessment ... as novel biomarkers will be used to investigate ...
... 2011 ReSearch Pharmaceutical Services, Inc. (RPS), a ... II-IV clinical development solutions to the biopharmaceutical and ... additions to its Operational and Senior Management team. ... as Chief Information Officer and Executive Vice President, ...
... PDL BioPharma, Inc. (PDL) (NASDAQ: ... second quarter financial results for the period ended June 30, 2011, ... will host a conference call and webcast that day at 4:30 ... Conference Call Details To access the live ...
Cached Biology Technology:Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis 2Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis 3RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 2RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 3PDL BioPharma Announces Second Quarter 2011 Financial Results on July 27, 2011 2
(Date:9/30/2014)... Ill. --- Do we think of nature as something that ... we need to "preserve?" Or do we think of ourselves ... part of nature, but what about a house? , ... are also reflected in our actions, our speech and in ... with the University of Washington, the American Indian Center of ...
(Date:9/30/2014)... captured the popular attention of both children and aquarium ... sold as dehydrated eggs, these tiny brine shrimp readily ... tank of salt water. , Physicists, though, are ... shrimp vertically migrate in large groups in response to ... night and retreating deeper during the day. , Two ...
(Date:9/30/2014)... led by Clemson University associate professor Brian Powell, ... the U.S. Department of Energy,s Experimental Program to ... impact on South Carolina in the advancement of ... "Understanding the scientific and engineering needs for safely ... technologies is imperative if South Carolina is to ...
Breaking Biology News(10 mins):The cultural side of science communication 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Researchers get $5.25 million to advance nuclear technologies in South Carolina 2
... 2008) -- Cell Press has been chosen by ... journal from January 2009. The Biophysical Society ... Journal content and that of the Cell Press ... and Structure. , For more than 50 years ...
... . , Iron is vital to human life; ... that makes our blood red and supplies our cells with ... thought that iron deposits in the brain contribute to certain ... Alzhiemers. A malfunction of the blood transporter transferrin may be ...
... new modeling approach to estimate sea ice thickness. This ... The model was developed by scientists with ... Sciences, Moscow. Using this new technique, the ... to 2003. Results showed that average ice thickness and ...
Cached Biology News:Cell Press announces new partnership with the Biophysical Society 2Rusty worms in the brain 2New method to estimate sea ice thickness 2
Request Info...
Recombinant Rat Leptin, Ultra Pure...
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: